
|Podcasts|September 9, 2021
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
Author(s)Urology Times staff
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
Advertisement
In this episode, Urology Times® Managing Editor Ben Saylor spoke with Amy E. Krambeck, MD. She discusses the recent Journal of Endourology study, "Multi-institutional prospective randomized control trial of novel intracorporeal lithotripters: ShockPulse-SE vs Trilogy trial," for which she served as senior author. Krambeck is a professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5






